Best menopause telehealth, ranked on credentials — not ad budget.

On credentialing alone, Midi Health and Alloy lead the US menopause telehealth market. Both staff their clinical teams primarily with Menopause Society Certified Practitioners (MSCP) and follow the 2022 Menopause Society Hormone Therapy Position Statement. Midi is the better pick for patients with in-network insurance; Alloy is the better pick for predictable cash-pay pricing.

Yes. All five services on this page — Midi Health, Alloy, Evernow, Winona, and Hers Menopause — prescribe FDA-approved systemic estrogen (oral and transdermal), micronized progesterone, and vaginal estrogen for genitourinary syndrome of menopause. Prescribing is performed by licensed clinicians in the patient’s state and follows the same hormone therapy indications the Menopause Society set out in its 2022 Position Statement (Menopause 29(7):767–794).

Coverage depends on the service. Midi Health is in-network with most major US health plans (Aetna, BCBS, Cigna, United, Medicare in many states); patients pay a standard copay. Alloy, Evernow, Winona, and Hers Menopause operate on a cash subscription model and do not bill insurance directly, though monthly fees are typically eligible for HSA/FSA reimbursement.

No. None of Midi, Alloy, Evernow, Winona, or Hers prescribe compounded pellet hormones. Compounded pellets are explicitly not recommended by the 2019 Global Consensus Position Statement on Testosterone Therapy for Women (J Clin Endocrinol Metab 104(10):4660–4666) and the 2022 Menopause Society Position Statement. We rank services that default to compounded pellets below FDA-approved-only formularies.

Cash-pay subscription pricing as of May 2026: Alloy from $49/month for symptom-focused care plus medication costs; Evernow from $99/month with medications included; Winona from $33/month plus medication; Hers Menopause from $29 initial visit. Midi Health bills insurance — typical copay $0–$50 — and offers a cash-pay option from approximately $99 per visit. Pricing is verified against each provider’s public pricing page on the retrieval date shown in the sources block.

See a local MSCP-credentialed physician for: a personal or first-degree-relative history of breast cancer, prior venous thromboembolism, undiagnosed abnormal uterine bleeding, prior failed HRT trial, conditions requiring pelvic exam or imaging, or care that must be coordinated with oncology or endocrinology. This is consistent with the contraindication list in the 2022 Menopause Society Hormone Therapy Position Statement.